Pfizer recalls mislabeled bottles of adult Robitussin

cough syrup on geometric table cloth

Pfizer's Consumer Healthcare is pulling tens of thousands of bottles of one of its adult Robitussin products in the U.S. due to a labeling issue. It comes just weeks after a different kind of manufacturing snafu led to the recall of its children's Advil products in Canada.

According to the most recent FDA Enforcement Report, Pfizer ($PFE) is voluntarily recalling 63,636 bottles of Adult Robitussin PEAK COLD Cough & Chest Congestion DM Liquid in 8-oz. bottles. The FDA report didn't give specifics, but according to a notice posted on the website of supermarket chain Wegmans, some of the PEAK COLD meds had been mislabeled as Adult Robitussin Maximum Strength Nighttime Cough DM. The recall began in February but was just posted this week by the FDA.

In February, Pfizer voluntarily recalled 126 lots of Children's Advil in Canada because "clumps" of the active ingredient ibuprofen could form in the bottle and lead to higher or lower doses given to infants and children if it the bottle was not shaken well before each use.

Cambrex Webinar

Understanding the Importance of Crystallization Processes to Avoid Unnecessary Cost, Risk and Development Delays

Wednesday, May 27, 2020 | 10am ET / 7am PT

A well-developed crystallization process can produce suitable particles that can facilitate consistent filtration, drying and formulation of the API and allow confident and reliable manufacturing of the final drug product, while avoiding unnecessary cost, risk and development delays.

In that case, the New York-based drugmaker said it discovered the problem during routine stability testing and tracked the problem to a change to an emulsifying ingredient (xanthan gum) from one of Pfizer's suppliers that allowed ibuprofen in the liquid suspension to separate over time. It said it had replaced the source of that ingredient.

- find the Pfizer recall here
- here's the Wegmans notice

Read more on

Suggested Articles

The eight-year deal will initially cover lupus drug Benlysta and could expand to other GSK specialty-care products in the future.

With a new £131 million contribution from the U.K. government, VMIC aims to both speed up and expand on its prior ambitions.

Pricing controversies shouldn't overshadow Phlow's promise to provide low-cost drugs to address COVID-19, says the CEO of partner Civica Rx.